

1 Technical Note

2 Chemical Proportionality within Molecular Networks

3 Daniel Petras^{1,2,#,*}, Andrés Mauricio Caraballo-Rodríguez^{1,2,#}, Alan K. Jarmusch^{1,2,3}, Carlos Molina-
4 Santiago⁴, Julia M. Gauglitz^{1,2}, Emily C. Gentry^{1,2}, Pedro Belda-Ferre⁵, Diego Romero⁴, Shirley M.
5 Tsunoda¹, Pieter C. Dorrestein^{1,2}, Mingxun Wang^{1,2*}

7 ¹ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla,
8 San Diego, CA, USA

9 ² Collaborative Mass Spectrometry Innovation Center, University of California San Diego, La Jolla, San
10 Diego, CA, USA

11 ³ Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences
12 (NIEHS), Research Triangle Park, NC, USA

13 ⁴ Instituto de Hortofruticultura Subtropical y Mediterránea “La Mayora”, Universidad de Málaga-Consejo
14 Superior de Investigaciones Científicas (IHSMUMA-CSIC), Departamento de Microbiología, Universidad
15 de Málaga, Bulevar Louis Pasteur 31 (Campus Universitario de Teatinos), 29071 Málaga, Spain.


16 ⁵ Department of Pediatrics, University of California San Diego, La Jolla, San Diego, CA, USA

17
18 #These authors contributed equally

19 *Correspondence should be addressed to Mingxun Wang (miw023@ucsd.edu) for questions regarding
20 software development and infrastructure and to Daniel Petras (functionalmetabolomics@gmail.com) for
21 questions regarding concept and experimental validation.

22
23 **Abstract:** Molecular networking of non-targeted tandem mass spectrometry data connects
24 structurally related molecules based on similar fragmentation spectra. Here we report the
25 Chemical Proportionality (ChemProp) contextualization of molecular networks. ChemProp scores
26 the changes of abundance between two connected nodes over sequential data series (e.g.
27 temporal or spatial relationships) which can be displayed as a direction within the network to
28 prioritize potential biological and chemical transformations or proportional changes of
29 (biosynthetically) related compounds. We tested the ChemProp workflow on a ground truth data
30 set of defined mixture and highlighted the utility of the tool to prioritize specific molecules within
31 biological samples, including bacterial transformations of bile acids, human drug metabolism and
32 bacterial natural products biosynthesis. The ChemProp workflow is freely available through the
33 Global Natural Products Social Molecular Networking (GNPS) environment.

34



35

36 **Key Words:** Metabolomics; Non-targeted Metabolomics; Tandem-Mass Spectrometry; Molecular
37 Networking; Biochemical Transformation; Data analysis

38 Introduction

39

40 To understand the metabolism of a given biological system, the identification of metabolites and
41 their dynamical changes through (bio)chemical transformation is fundamentally important. Many
42 metabolomics studies, that make use of non-targeted tandem mass spectrometry (MS/MS), are
43 performed in a longitudinal or spatial fashion.^{1,2} From such data, one can hypothesize the extent
44 of putative (bio)chemical modifications by correlating changes in peak area that are associated
45 with temporal or spatial patterns.

46 There are numerous challenges in the interpretation of non-targeted mass spectrometry
47 data. Two fundamental challenges are the annotation of MS/MS spectra and providing meaningful
48 interpretation of the biological role of the numerous compounds detected. Molecular networking
49 in the GNPS web platform (gnps.ucsd.edu) aims to tackle the former challenge in annotation by
50 connecting similar compounds based on their MS/MS spectra, which reflects similarities in
51 chemical structure.³⁻⁵ By doing so, molecular networking provides a framework of chemical-
52 structural similarity in non-targeted MS/MS data upon which additional information can be
53 displayed such as relative metabolite abundance.⁶ In addressing the latter challenge of identifying
54 potential (metabolic) transformations, several approaches have been described. A paired mass
55 distance (PMD) approach was developed to link biochemical reactions available in databases,⁷
56 such as KEGG,⁸ through prediction of chemical transformations based on mass differences. Meta-
57 mass shift analysis is focused on all the mass differences within molecular networks,⁹ irrespective
58 of whether a known metabolite has been mapped onto biochemical pathways. The use of
59 commonly observed delta masses for modification searches is also used in proteomic studies,
60 where the mass difference between two observed peptides arise via genetic changes, or via post-
61 translational and chemical modifications.¹⁰

62 We developed a chemical proportionality (ChemProp) approach, integrated with feature-
63 based molecular networking³ to address the challenge in identifying related metabolites in non-
64 targeted MS/MS data. ChemProp aims to find two or more structurally related molecules that have
65 a proportional relationship to each other between sequential data series (*e.g.* time or space). For
66 example, a (bio)chemical reaction that causes the mass difference ($\Delta m/z$) of 14.016 could result
67 both from a methylation or a demethylation reaction, but current methodology does not highlight
68 or in any way indicate that these changes are associated to spatial or temporal data. ChemProp
69 scores the peak area changes of connected nodes in a molecular network across a sequential
70 data frame by comparing their proportions. The ChemProp scoring can be used to guide the
71 formulation of hypotheses regarding the direction of the change, that can be indicated directly
72 within a molecular network or used on a dataset level to explore pattern changes between all
73 connected compounds (**Figure 1**).

74 In this technical note, we present illustrative examples of insights gained via ChemProp in
75 the case of a defined mixture (*i.e.* ground truth dataset) that illustrates an acetylation reaction of
76 sulfamethoxazole, biological datasets of bacterial transformations of bile acids, human drug
77 metabolism of omeprazole and proportional changes in the biosynthesis of bacterial natural
78 products.

79

80 Experimental Concept




81
82 The concept of ChemProp is illustrated in Figure 1a and b. In order to establish a proportion based
83 directionality of potential transformations or pattern change of structurally related compounds,
84 ChemProp relies on the following assumptions. The first is that a given reactant and product or
85 two otherwise structurally related compounds are connected in a molecular network through their
86 MS/MS (chemical) similarity. And second, that the abundance of the initial compound would
87 decrease over time/space and the abundance of the new compound would increase.

88 To obtain this information, ChemProp makes use of Feature-based Molecular Networking
89 (FBMN)⁶ and the peak areas of a given feature pair (connected in the networking, e.g. Compound
90 A and B in Figure 1a) across a sequential data series. The ChemProp score is derived via the
91 log-ratio of the proportional value of feature pairs at one time point vs. the proportional value at a
92 sequential time point.

93 In the hypothetical example in **Figure 1a**, this would correspond to the log-ratio of A_1/B_1 by A_2/B_2 .
94 In practice, samples 1 and 2 can be time points in a longitudinal study, but also data points in a
95 spatial study, or other experimental designs such as two treatment groups. Note, a constant ($k =$
96 1.0×10^{-10}) is added to each value to avoid any zero values before calculating the ratio. A positive
97 ChemProp score indicates a forward change ($A \rightarrow B$), whereas a negative ChemProp score
98 indicates a reversed change ($B \rightarrow A$).

99 Figure 1b showcases different examples of relations that would be captured with high scores as
100 well as challenging relations that would result in low scores. The magnitude of the change in
101 abundance is thereby reflected in the absolute changes in proportions and represented as a
102 ChemProp score (the higher the score, the higher the ratio). As a default cut-off we recommend
103 to use a ChemProp score of 2, which would represent a 10-fold change in the feature pair.
104 However, an optimal cut-off is compound and study dependent.

105 The input required to perform the ChemProp workflow is a FBMN GNPS task ID from a job that
106 includes metadata indicating the sequential order of samples. We recommend using the ReDU
107 metadata template,¹⁶ that is validated to be compatible with ChemProp. The output of the
108 ChemProp workflow consists of a .graphML file which can be directly loaded into network
109 visualization software such as Cytoscape. The .graphML is a summary file that contains the delta
110 mass as well as ChemProp and cosine scores of the connected nodes. The sign of the ChemProp
111 score can be used to map the directionality in the form of arrows in Cytoscape. In addition to the
112 .graphML network file, ChemProp also provides a tabulated output of node connections, delta
113 masses and ChemProp scores as a .csv file that can be used for further statistical analysis of
114 global transformations within datasets.



115
 116 **Figure 1. ChemProp concept, expected scenarios and ground truth experiment.**
 117 (a) Concept illustrated with the example of the (bio)chemical formation of N-acetyl sulfamethoxazole. (b)
 118 Plausible scenarios captured by the ChemProp approach. (c) Observed abundance changes (Y axis) of
 119 sulfamethoxazole and acetyl-sulfamethoxazole in a demonstration of proof-of-concept data (concentration
 120 X axis). If T1 (98 µg/mL; 2 µg/mL) and T2 (2 µg/mL; 98 µg/mL) are considered as two time points, the
 121 resulting chemical directionality in the molecular network indicates an acetylation reaction (+ *m/z* 42.01).
 122

Results and Discussion

To evaluate the ChemProp approach, defined mixtures of sulfamethoxazole and N-acetyl-sulfamethoxazole in a dilution series with linear changing proportion were created and analyzed. The resulting peak areas and molecular network are shown in **Figure 1c**. The defined mixture mimics an acetylation reaction with linear conversion of reactants to products over time which represents a common metabolic phase II reaction and microbial resistance strategy (excluding reaction kinetics).^{11,12} Looking at the experimentally derived peak areas of sulfamethoxazole and N-acetyl-sulfamethoxazole, an expected anti-correlation was observed. The maximum ChemProp score was 7.80 between concentration point 1 and 7, which are considered as T1 (98 ug/mL A; 2 ug/mL B) and T2 (2 ug/mL A; 98 ug/mL B), representing the largest differences in the mock acetylation reaction.

To test ChemProp with real-life samples, we applied the workflow to three publicly available MS/MS datasets. All datasets were from studies with temporal sampling. In order to explore all datasets for putative transformations and identify patterns of frequent reactions (mass shifts), we plotted the delta masses from all molecular networks from data sets against their particular ChemProp score. The global transformation patterns for all four data sets can be evaluated between the datasets and are shown in **Figure 2a**. The results reveal that different time dependent (biological) changes are distinct to each experiment. For instance, the anaerobic culturing of *Clostridium cadaveris* showed more frequently negative ChemProp scores, indicating mass losses (e.g. demethylation or dehydration). ChemProp can thus give insights into catabolic, or anabolic behavior, and can highlight the frequency of particular mass shifts/modifications.

In the example of microbial transformations of bile acids, cholic acid and deoxycholic acid were added to a *Clostridium cadaveris* culture and incubated. After extraction and LC-MS/MS analysis, the ChemProp workflow was applied to identify potential bile acid transformation products. Figure 2b shows a molecular network of a subset of bile acids detected in the culture extracts. High ChemProp scores were observed between nodes of deoxycholic acid (DCA) (detected as $[M-3H_2O+H]^+$) or cholic acid (CA) (detected as $[M-H_2O+H]^+$) and leucine conjugated deoxycholic acid (Leu-DCA). Based on *a priori* knowledge that the bile acids were fed to the culture, we hypothesize that either parent bile acid could be the substrate for formation of Leu-DCA. The conversion of CA to Leu-DCA would require a conjugation to leucine and dehydroxylation. There was also alanine conjugated CA (Ala-CA) detected but the deoxycholic derivative was not observed. Looking at the abundance change in these relationships, the ChemProp score reflects the decrease of CDCA and CA over time while Ala-CA and Leu-CDCA increase (Figure S1).

Next, we applied ChemProp to a dataset from a study that investigated the metabolism of omeprazole¹³, a proton pump inhibitor drug, in healthy humans. **Figure 2c** displays the molecular network component in which omeprazole, 5-hydroxyomeprazole and carboxyomeprazole (omeprazole metabolites), and a deuterated standard (*i.e.* omeprazole- d_3) were detected. Further, a phase II metabolite, hydroxyomeprazole-5-O-glucuronide was connected in the network. The largest ChemProp value observed was 2.89 between the omeprazole-omeprazole- d_3 node pair, (60 to 120 min time interval). We observed that omeprazole- d_3 remains constant (as it was spiked into each sample), while the level of omeprazole increased from 60 to 120 min (Figure S2). While not offering any biological insight, this observation supports the intended measure of ChemProp. On the other hand, the CYP2C19 transformation of omeprazole to 5-hydroxyomeprazole, a



167 primary metabolite of omeprazole which is of biological relevance, had a ChemProp value of 0.45.
168 While the absolute ChemProp value was smaller than that of other test cases within the study,
169 the value was sufficient to be prioritized as interesting and was found to reflect the combined
170 effect of pharmacokinetic absorption from the orally dosed (single dosage) omeprazole into the
171 blood plasma, as well as the subsequent metabolism by CYP2C19 in the intestine and liver.
172 Combined absorption and metabolism is reflected in the omeprazole-carboxyomeprazole node
173 pair. The hydroxyomeprazole-5-O-glucuronide and 5-hydroxyomeprazole node pair had a greater
174 ChemProp value (2.02) during the 60 to 120 min interval which reflects the lesser signal of
175 glucuronide metabolite as its formation is dependent on the 5-hydroxyomeprazole precursor
176 (Figure S2).

177 Lastly, we applied the ChemProp approach to explore the production of bacterial natural products.
178 Over a culturing time course of *Bacillus subtilis*, the production of different surfactin derivatives, a
179 class of well-known and characteristic lipopeptides¹⁴, changed in time dependent fashion (**Figure**
180 **2d** and **Figure S3**). From a biological perspective, we expected a change of surfactin levels over
181 time as they have been described in the context of motility in *B. subtilis*¹⁵. We observed two
182 clusters of surfactin derivatives with similar ChemProp patterns. Notably, while the first group of
183 surfactins A-E (Figure 2d and Figure S3, left side of network) did not show strong variance over
184 the time course (low ChemProp score), the second cluster of surfactin derivatives (m/z 1036.69
185 and m/z 1067.73, right side of the network), started to increase after 24h of cultivation (high
186 ChemProp score, relationship 2). According to these proportional changes, the network shows
187 high ChemProp scores within the two groups of compounds (2.4-3.1) and low scores within these
188 groups (0.04-0.5). The observed mass differences with the networks were $\Delta m/z$ 14.02 and Δ
189 m/z 28.04 which correspond to methylations or variations in the amino acids incorporated during
190 the biosynthesis of these bacterial metabolites¹⁶. However, less frequently observed mass shifts
191 occurred between the two derivative groups (left and right side of network) with $\Delta m/z$ 31.04 and
192 $\Delta m/z$ 45.05 (Figure 3d) that are differentially produced over the time course.

193 Looking at the MS/MS spectra of the differential expressed variants (m/z 1036.69 and m/z
194 1067.73) both compounds contain a shared MS/MS fragment ion of m/z 685 $[M+H]^+$ (y_6+H_2O) that
195 suggests amino acid composition (e.g. Leu/Ile-Leu/Ile-Val-Asp-Leu/Ile-Leu/Ile) (Figure S4), other
196 fragments such as m/z 356 and m/z 370 indicate chemical variations, likely present at the ω -
197 hydroxy fatty acid chain, which we speculate could indicate the requirement of a different enzyme
198 and/or signaling pathway that changed over the time course of *B. subtilis* growth.

199 This example highlights that ChemProp can be used to identify directionality of actual
200 (biochemical) reactions and to highlight potential pattern changes of structurally /biochemically
201 related compounds.

202 For both scenarios, it is important to note that the proportionality approach should be considered
203 as a prioritization and hypothesis generating strategy that complements chemical information
204 provided by the feature-based molecular networking workflow.



205

206

207

208

209

210

211

212

213

214

215

Figure 2: Global analysis and examples of captured directionality from test datasets.

(a) Summary of delta mass shifts captured from complex datasets including drug metabolism, bile acids, and fungal interaction. (b) Molecular network of bile acid modifications, highlighting conjugations with common amino acids. This example corresponds to relationships 2 and 3 (shown in Figure 1). (c) Network of detected features from a drug metabolism dataset involving omeprazole and its hydroxylated modification mediated by cytochrome P450. This example of drug metabolism corresponds to relationship 2 (shown in Figure 1). (d) Network of surfactins produced by *Bacillus subtilis* over a time course experiment. This example corresponds to relationships 2, 3 and 4 (shown in Figure 1).

216 **Conclusion**

217
218 Molecular Networking aims to enhance chemical insight from non-targeted MS/MS experiments
219 by connecting spectrally-related and thus structurally-related compounds. The ChemProp
220 approach facilitates the prioritization of relative changes of connected nodes within molecular
221 networks over sequential data series (e.g. time or space). ChemProp thus enhances one's' ability
222 to formulate hypotheses from non-targeted LC-MS/MS data with respect to mass changes in a
223 biological context, such as microbial modifications, drug metabolism, and changes in biosynthesis
224 patterns. The proportionality approach can be used to suggest directionality of (bio)chemical
225 reactions in time-courses, spatial mapping, or treatment/control experiments and in a broader
226 sense, to highlight abundance pattern changes among related compounds.

227 **Data and Software availability**

228
229 There are two portions of the ChemProp infrastructure, ChemProp GNPS/ProteoSAFe workflow
230 and the ChemProp Results Exploration Dashboard. The citable source code is available at
231 10.5281/zenodo.4081635 and active development is at GitHub: [https://github.com/CCMS-](https://github.com/CCMS-UCSD/GNPS_Workflows/tree/master/chemprop)
232 [UCSD/GNPS_Workflows/tree/master/chemprop](https://github.com/CCMS-UCSD/GNPS_Workflows/tree/master/chemprop).

233
234 The ChemProp workflow is available through the GNPS environment and github at:
235 [https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22%3A%20%22CHE](https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22%3A%20%22CHEMPROP%22%7D)
236 [MPROP%22%7D](https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22%3A%20%22CHEMPROP%22%7D).

237 Detailed instructions, including a step-to-step tutorial, for the use of ChemProp is available
238 through the GNPS documentation: <https://ccms-ucsd.github.io/GNPSDocumentation/chemdir/>.

239 All raw and centroid MS/MS data used in this manuscript can be downloaded from the MassIVE
240 repository under the following accession numbers: MSV000085688, MSV000084681,
241 MSV000082493, MSV000082402.

242 **Acknowledgements**

243
244 A.M.C.R. and P.C.D. were supported by the National Sciences Foundation grant IOS-1656481
245 and National Institutes of Health Award 1DP2GM137413-01. D.R. was founded by ERC Starting
246 Grant (BacBio 637971) and Ministerio de Ciencia e Innovación (PID2019-107724GB-I00). We
247 thank Dr. Krista Longnecker and all other participants of the ChemProp online Workshop for their
248 feedback or helpful discussion.

249 **Author contributions**

250
251 DP and AMCR conceived the concept of ChemProp. MW implemented ChemProp into the GNPS
252 environment. DP, AMCR, AKJ, CMS, DR, JMG, ECG and PBF performed sample preparation,
253 MS/MS experiments, analyzed data and validated the ChemProp workflow. SMT provided data
254 and analysis for the omeprazole example. PCD provided guidance, feedback and infrastructure.
255 All authors wrote and edited the manuscript.

256
257
258
259

260 **Ethics declarations**

261
262 Mingxun Wang is a co-founder of Ometa labs LLC. Pieter C. Dorrestein is a scientific advisor for
263 Sirenas LLC, Cybele Microbiome and Galileo and a scientific advisor and co-founder of Ometa
264 labs LLC and Enveda with approval by UCSD.

265
266 **References**

- 267
268 (1) Stewart, C. J.; Embleton, N. D.; Marrs, E. C. L.; Smith, D. P.; Fofanova, T.; Nelson, A.;
269 Skeath, T.; Perry, J. D.; Petrosino, J. F.; Berrington, J. E.; Cummings, S. P. Longitudinal
270 Development of the Gut Microbiome and Metabolome in Preterm Neonates with Late
271 Onset Sepsis and Healthy Controls. *Microbiome* **2017**, *5* (1), 75.
272 <https://doi.org/10.1186/s40168-017-0295-1>.
- 273 (2) Petras, D.; Jarmusch, A. K.; Dorrestein, P. C. From Single Cells to Our Planet—Recent
274 Advances in Using Mass Spectrometry for Spatially Resolved Metabolomics. *Curr. Opin.*
275 *Chem. Biol.* **2017**, *36*, 24–31. <https://doi.org/10.1016/j.cbpa.2016.12.018>.
- 276 (3) Watrous, J.; Roach, P.; Alexandrov, T.; Heath, B. S.; Yang, J. Y.; Kersten, R. D.; van der
277 Voort, M.; Pogliano, K.; Gross, H.; Raaijmakers, J. M.; Moore, B. S.; Laskin, J.; Bandeira,
278 N.; Dorrestein, P. C. Mass Spectral Molecular Networking of Living Microbial Colonies.
279 *Proc Natl Acad Sci U A* **2012**, *109* (26), E1743-52.
280 <https://doi.org/10.1073/pnas.1203689109>.
- 281 (4) Wang, M.; Carver, J. J.; Phelan, V. V.; Sanchez, L. M.; Garg, N.; Peng, Y.; Nguyen, D. D.;
282 Watrous, J.; Kaponov, C. A.; Luzzatto-Knaan, T.; Porto, C.; Bouslimani, A.; Melnik, A. V.;
283 Meehan, M. J.; Liu, W.-T.; Crüsemann, M.; Boudreau, P. D.; Esquenazi, E.; Sandoval-
284 Calderón, M.; Kersten, R. D.; Pace, L. A.; Quinn, R. A.; Duncan, K. R.; Hsu, C.-C.; Floros,
285 D. J.; Gavilan, R. G.; Kleigrewe, K.; Northen, T.; Dutton, R. J.; Parrot, D.; Carlson, E. E.;
286 Aigle, B.; Michelsen, C. F.; Jelsbak, L.; Sohlenkamp, C.; Pevzner, P.; Edlund, A.;
287 McLean, J.; Piel, J.; Murphy, B. T.; Gerwick, L.; Liaw, C.-C.; Yang, Y.-L.; Humpf, H.-U.;
288 Maansson, M.; Keyzers, R. A.; Sims, A. C.; Johnson, A. R.; Sidebottom, A. M.; Sedio, B.
289 E.; Klitgaard, A.; Larson, C. B.; P, C. A. B.; Torres-Mendoza, D.; Gonzalez, D. J.; Silva, D.
290 B.; Marques, L. M.; Demarque, D. P.; Pociute, E.; O'Neill, E. C.; Briand, E.; Helfrich, E. J.
291 N.; Granatosky, E. A.; Glukhov, E.; Ryffel, F.; Houson, H.; Mohimani, H.; Kharbush, J. J.;
292 Zeng, Y.; Vorholt, J. A.; Kurita, K. L.; Charusanti, P.; McPhail, K. L.; Nielsen, K. F.;
293 Vuong, L.; Elfeki, M.; Traxler, M. F.; Engene, N.; Koyama, N.; Vining, O. B.; Baric, R.;
294 Silva, R. R.; Mascuch, S. J.; Tomasi, S.; Jenkins, S.; Macherla, V.; Hoffman, T.; Agarwal,
295 V.; Williams, P. G.; Dai, J.; Neupane, R.; Gurr, J.; Rodríguez, A. M. C.; Lamsa, A.; Zhang,
296 C.; Dorrestein, K.; Duggan, B. M.; Almaliti, J.; Allard, P.-M.; Phapale, P.; Nothias, L.-F.;
297 Alexandrov, T.; Litaudon, M.; Wolfender, J.-L.; Kyle, J. E.; Metz, T. O.; Peryea, T.;
298 Nguyen, D.-T.; VanLeer, D.; Shinn, P.; Jadhav, A.; Müller, R.; Waters, K. M.; Shi, W.; Liu,
299 X.; Zhang, L.; Knight, R.; Jensen, P. R.; Palsson, B. O.; Pogliano, K.; Lington, R. G.;
300 Gutiérrez, M.; Lopes, N. P.; Gerwick, W. H.; Moore, B. S.; Dorrestein, P. C.; Bandeira, N.
301 Sharing and Community Curation of Mass Spectrometry Data with Global Natural
302 Products Social Molecular Networking. *Nat Biotechnol* **2016**, *34* (8), 828–837.
303 <https://doi.org/10.1038/nbt.3597>.
- 304 (5) Aron, A. T.; Gentry, E. C.; McPhail, K. L.; Nothias, L.-F.; Nothias-Esposito, M.;
305 Bouslimani, A.; Petras, D.; Gauglitz, J. M.; Sikora, N.; Vargas, F.; van der Hooff, J. J. J.;
306 Ernst, M.; Kang, K. B.; Aceves, C. M.; Caraballo-Rodríguez, A. M.; Koester, I.; Weldon, K.
307 C.; Bertrand, S.; Roullier, C.; Sun, K.; Tehan, R. M.; P, C. A. B.; Christian, M. H.;
308 Gutiérrez, M.; Ulloa, A. M.; Tejada Mora, J. A.; Mojica-Flores, R.; Lakey-Beitia, J.;

- 309 Vázquez-Chaves, V.; Zhang, Y.; Calderón, A. I.; Tayler, N.; Keyzers, R. A.; Tugizimana,
310 F.; Ndlovu, N.; Aksenov, A. A.; Jarmusch, A. K.; Schmid, R.; Truman, A. W.; Bandeira, N.;
311 Wang, M.; Dorrestein, P. C. Reproducible Molecular Networking of Untargeted Mass
312 Spectrometry Data Using GNPS. *Nat. Protoc.* **2020**, *15* (6), 1954–1991.
313 <https://doi.org/10.1038/s41596-020-0317-5>.
- 314 (6) Nothias, L.-F.; Petras, D.; Schmid, R.; Dührkop, K.; Rainer, J.; Sarvepalli, A.; Protsyuk, I.;
315 Ernst, M.; Tsugawa, H.; Fleischauer, M.; Aicheler, F.; Aksenov, A. A.; Alka, O.; Allard, P.-
316 M.; Barsch, A.; Cachet, X.; Caraballo-Rodriguez, A. M.; Da Silva, R. R.; Dang, T.; Garg,
317 N.; Gauglitz, J. M.; Gurevich, A.; Isaac, G.; Jarmusch, A. K.; Kameník, Z.; Kang, K. B.;
318 Kessler, N.; Koester, I.; Korf, A.; Le Gouellec, A.; Ludwig, M.; H, C. M.; McCall, L.-I.;
319 McSayles, J.; Meyer, S. W.; Mohimani, H.; Morsy, M.; Moyne, O.; Neumann, S.;
320 Neuweber, H.; Nguyen, N. H.; Nothias-Esposito, M.; Paolini, J.; Phelan, V. V.; Pluskal, T.;
321 Quinn, R. A.; Rogers, S.; Shrestha, B.; Tripathi, A.; van der Hoof, J. J. J.; Vargas, F.;
322 Weldon, K. C.; Witting, M.; Yang, H.; Zhang, Z.; Zubeil, F.; Kohlbacher, O.; Böcker, S.;
323 Alexandrov, T.; Bandeira, N.; Wang, M.; Dorrestein, P. C. Feature-Based Molecular
324 Networking in the GNPS Analysis Environment. *Nat. Methods* **2020**, *17* (9), 905–908.
325 <https://doi.org/10.1038/s41592-020-0933-6>.
- 326 (7) Yu, M.; Petrick, L. Reactomics: Using Mass Spectrometry as a Reaction Detector. *bioRxiv*
327 **2020**, 855148. <https://doi.org/10.1101/855148>.
- 328 (8) Kanehisa, M.; Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic*
329 *Acids Res.* **2000**, *28* (1), 27–30. <https://doi.org/10.1093/nar/28.1.27>.
- 330 (9) Hartmann, A. C.; Petras, D.; Quinn, R. A.; Protsyuk, I.; Archer, F. I.; Ransome, E.;
331 Williams, G. J.; Bailey, B. A.; Vermeij, M. J. A.; Alexandrov, T.; Dorrestein, P. C.; Rohwer,
332 F. L. Meta-Mass Shift Chemical Profiling of Metabolomes from Coral Reefs. *Proc Natl*
333 *Acad Sci U S A* **2017**, *114* (44), 11685–11690. <https://doi.org/10.1073/pnas.1710248114>.
- 334 (10) Avtonomov, D. M.; Kong, A.; Nesvizhskii, A. I. DeltaMass: Automated Detection and
335 Visualization of Mass Shifts in Proteomic Open-Search Results. *J Proteome Res* **2019**,
336 *18* (2), 715–720. <https://doi.org/10.1021/acs.jproteome.8b00728>.
- 337 (11) Pluvinage, B.; Dairou, J.; Possot, O. M.; Martins, M.; Fouet, A.; Dupret, J.-M.; Rodrigues-
338 Lima, F. Cloning and Molecular Characterization of Three Arylamine N-Acetyltransferase
339 Genes from *Bacillus Anthracis*: Identification of Unusual Enzymatic Properties and Their
340 Contribution to Sulfamethoxazole Resistance. *Biochemistry* **2007**, *46* (23), 7069–7078.
- 341 (12) Reis, P. J. M.; Homem, V.; Alves, A.; Vilar, V. J. P.; Manaia, C. M.; Nunes, O. C. Insights
342 on Sulfamethoxazole Bio-Transformation by Environmental Proteobacteria Isolates. *J*
343 *Hazard. Mater.* **2018**, *358*, 310–318. <https://doi.org/10.1016/j.jhazmat.2018.07.012>.
- 344 (13) Jarmusch, A. K.; Vrbanac, A.; Momper, J. D.; Ma, J. D.; Alhaja, M.; Liyanage, M.; Knight,
345 R.; Dorrestein, P. C.; Tsunoda, S. M. Enhanced Characterization of Drug Metabolism and
346 the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and
347 Untargeted Metabolomics Study. *Clin. Transl. Sci.* *n/a* (n/a).
348 <https://doi.org/10.1111/cts.12785>.
- 349 (14) Moro, G. V.; Almeida, R. T. R.; Napp, A. P.; Porto, C.; Pilau, E. J.; Lüdtkke, D. S.; Moro, A.
350 V.; Vainstein, M. H. Identification and Ultra-High-Performance Liquid Chromatography
351 Coupled with High-Resolution Mass Spectrometry Characterization of Biosurfactants,
352 Including a New Surfactin, Isolated from Oil-Contaminated Environments. *Microb.*
353 *Biotechnol.* **2018**, *11* (4), 759–769. <https://doi.org/10.1111/1751-7915.13276>.
- 354 (15) Molina-Santiago, C.; Pearson, J. R.; Navarro, Y.; Berlanga-Clavero, M. V.; Caraballo-
355 Rodriguez, A. M.; Petras, D.; García-Martín, M. L.; Lamon, G.; Habenstein, B.; Cazorla, F.
356 M. The Extracellular Matrix Protects *Bacillus Subtilis* Colonies from *Pseudomonas*
357 Invasion and Modulates Plant Co-Colonization. *Nat. Commun.* **2019**, *10* (1), 1–15.
- 358 (16) Hu, F.; Liu, Y.; Li, S. Rational Strain Improvement for Surfactin Production: Enhancing the
359 Yield and Generating Novel Structures. *Microb. Cell Factories* **2019**, *18* (1), 1–13.